PUMA Activators
Common PUMA Activators include, but are not limited to Suberoylanilide Hydroxamic Acid CAS 149647-78-9, Nutlin-3 CAS 548472-68-0, Etoposide (VP-16) CAS 33419-42-0, Doxorubicin CAS 23214-92-8 and Selumetinib CAS 606143-52-6.
PUMA Activators constitute a distinctive subset of chemical compounds characterized by their unique capability to modulate the activity of the p53-upregulated modulator of apoptosis (PUMA) protein. Operating through specific interactions, this chemical class engages with and enhances the signaling pathways associated with PUMA, a critical regulator of cellular apoptosis. PUMA, known for its role in promoting programmed cell death, serves as a pivotal component in initiating the intrinsic apoptotic pathway-an essential process for maintaining cellular homeostasis.
The operational principles of PUMA Activators involve precise molecular interactions that possess the potential to amplify downstream effects within PUMA-mediated signaling. This modulation capacity contributes to the orchestration of apoptotic processes and cellular responses to stress. The intricate mechanisms through which PUMA Activators impact PUMA-related pathways are currently subjects of ongoing scientific investigation. These endeavors not only deepen our understanding of the intricate interplay between survival and death signals within cells but also provide insights into the regulatory network governing apoptotic processes. The specific modes of engagement between PUMA Activators and PUMA highlight the significance of this chemical class in unraveling the complexities of apoptotic regulation, offering applications across diverse scientific domains. As research continues to decipher the precise molecular interactions orchestrated by PUMA Activators, they emerge as valuable tools for advancing our understanding of cellular regulation and contributing to the broader landscape of scientific knowledge.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Suberoylanilide Hydroxamic Acid | 149647-78-9 | sc-220139 sc-220139A | 100 mg 500 mg | $133.00 $275.00 | 37 | |
HDAC inhibitors like vorinostat can alter chromatin structure, potentially enhancing accessibility of PUMA's promoter and thereby increasing PUMA transcription. | ||||||
Nutlin-3 | 548472-68-0 | sc-45061 sc-45061A sc-45061B | 1 mg 5 mg 25 mg | $62.00 $225.00 $779.00 | 24 | |
Nutlin-3 is known to activate p53, which can induce PUMA expression as part of the p53-mediated apoptotic pathway. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Etoposide is a topoisomerase inhibitor that can trigger DNA damage responses and possibly lead to PUMA upregulation. | ||||||
Resveratrol | 501-36-0 | sc-200808 sc-200808A sc-200808B | 100 mg 500 mg 5 g | $80.00 $220.00 $460.00 | 64 | |
Resveratrol has been investigated for its potential to activate p53 and, by extension, impact PUMA expression. | ||||||
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $176.00 $426.00 | 43 | |
Doxorubicin induces DNA damage and can activate p53, possibly affecting PUMA expression. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
A MEK inhibitor that could potentially impact PUMA expression by modulating the MAPK pathway and its downstream effects on p53. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Induces endoplasmic reticulum (ER) stress, which might activate p53-mediated pathways and influence PUMA expression. | ||||||
Cisplatin | 15663-27-1 | sc-200896 sc-200896A | 100 mg 500 mg | $138.00 $380.00 | 101 | |
A DNA-damaging agent used in chemotherapy, it activates p53 and could lead to PUMA upregulation as part of the p53 pathway. | ||||||
Chrysin | 480-40-0 | sc-204686 | 1 g | $38.00 | 13 | |
Investigated for its potential to activate p53, Chrysin might influence PUMA expression through p53-mediated mechanisms. | ||||||
Troglitazone | 97322-87-7 | sc-200904 sc-200904B sc-200904A | 5 mg 10 mg 25 mg | $110.00 $204.00 $435.00 | 9 | |
As a PPARγ agonist, Troglitazone has been suggested to impact PUMA expression in certain cellular contexts. | ||||||